Dr.Reddy’s Laboratories has entered into a definitive agreement with Teva Pharmaceutical Industries and an affiliate of Allergan to acquire a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the US for US $ 350 million in cash at closing.
Orienting on the facets of Green Chemistry and Engineering, Director API-R&D, Dr Reddy’s Laboratories, India, Dr Rakeshwar Bandichhor details why its practice is encouraging and elaborates the significance of academic-industry partnership for a healthy, innovative environment in the Indian pharma sector. Excerpts of the interview…
Dr. Reddy’s Laboratories plans to OctoPlus N.V. a service based specialty pharmaceutical company, for OctoPlus N.V. , for an offer price of € 27.39 million. This deal will help expand the expertise and scientific capabilities of Dr. Reddy's.
The Custom Pharmaceutical Services (CPS) business of Dr. Reddy’s Laboratories announced expansion in the areas of activated mPEG manufacturing and in the development and manufacture of NCE (New Chemical Entities) APIs for use in pre-clinical through to commercial development at its manufacturing facility in Mirfield, UK.
German pharma giant Merck and generics specialist Dr. Reddy of India have come together to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). The partnership covers co-development, manufacturing and commercialization of the compounds around the globe, with some specific country exceptions.